They demonstrate that, in EOC, GILZ increases tumor cell proliferation, activates AKT, down-regulates p21 and promotes cyclin D1 expression; all these molecules are involved in the progression of malignant tumors and their deregulations are often associated to poor clinical outcome [43-46,25]. This evidence concerns the gene AKT1 and neoplasm.